Vancomycin Containing PLLA/beta-TCP Controls MRSA In Vitro


Kankilic B., Bayramli E., Kilic E., Dagdeviren S., Korkusuz F.

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, vol.469, no.11, pp.3222-3228, 2011 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 469 Issue: 11
  • Publication Date: 2011
  • Doi Number: 10.1007/s11999-011-2082-9
  • Journal Name: CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.3222-3228

Abstract

Osteomyelitis caused by Methicillin-resistant Staphylococcus aureus (MRSA) often requires surgery and prolonged systemic antibiotic treatment. Local antibiotic delivery systems of bioceramics or polymers have been developed to treat osteomyelitis. A disadvantage of biodegradable polymers is the initial burst of antibiotics into the environment; one advantage of bioceramics is its osteoconductivity. We therefore developed a vancomycin-containing poly-l-lactic acid/beta-tricalcium phosphate (PLLA/beta-TCP) composite to control antibiotic release and stimulate bone formation.